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Interstitial laser hyperthermia: a new approach for treating liver
metastases
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Departments of'Surgery and2Radiology, University College and Middlesex Hospitals, London, UK
Summary The palliative management of hepatic metastases remains unsatisfactory. There is a need for a
simple non invasive technique which can stop or retard the rate of tumour growth. In principle, Interstitial
Laser hyperthermia may fulfil such a role. In experimental studies, this technique produced precise in situ
necrosis within solid organs which healed safely. In a pilot feasibility study, we treated ten patients with a total
of 18 hepatic metastases on 31 occasions using a percutaneous approach to achieve an overall objective
response rate of 44%. The treatment proved simple to perform, was well tolerated and produced radiological
evidence of necrosis in small metastases (diameter < 3 cm). However, further research is required before the
technique can be regarded as established. Its future role in most cases will be to control the growth of discrete
hepatic metastases unsuitable for resection. In instances where the extent of necrosis can be matched
accurately to tumour volume, the potential for cure exists.
Interstitial Laser Hyperthermia (ILH), an exciting new tech-
nique first described in 1983 using the Neodymium: YAG
laser (Nd:YAG), is simple both in concept and execution
(Bown, 1983). Its basis is the ability to transmit the infra red
wavelength of YAG laser light (1064 nm)-an intense energy
source, down thin calibre (0.1-0.6 mm) flexible silica or glass
fibres with virtually no energy loss. Such small fibre
diameters cause negligible tissue damage from their insertion.
The light emitting end can be delivered percutaneously into
the centre of solid organs (interstitial placement) within the
peritoneal cavity using ultrasound guidance with minimal
disturbance to the overlying abdominal wall. In contrast to
the high powers (50-70 watts) and short exposure times
(< 1.0 s) used with the Nd:YAG laser to recanalise obstruc-
ting foregut cancers, ILH requires much lower powers
(0.5-2.0 watts) with long exposure times (200-1000 s). The
laser light is therefore delivered in a more gentle and con-
trolled manner to be absorbed as heat producing a zone of
tissue necrosis centred around the fibre tip. The treated area
is left in situ to undergo resorption with healing by regenera-
tion and/or fibrosis. In the field of oncology, the prospect of
achieving accurate in situ necrosis of malignant tissue simply
and atraumatically may obviate, in certain instances, the
necessity for surgical excision with its attendant hazards and
cost.
Experimental work using a single fibre positioned at
laparotomy in normal rat liver has produced well defined,
reproducible areas of necrosis up to 15 mm in diamter; the
diameter being a function of the applied laser power and
exposure times (Matthewson et al., 1987). Similar intra-
operative studies have also been performed in canine liver
using four fibres in juxtaposition fired simultaneously from a
single laser (Steger et al., 1988). At 1 week, well defined
confluent areas of necrosis up to 3.5 cm in diameter were
obtained. These were roughly spherical and centred around
the fibres. Such areas were clearly delineated by ultrasound
(US) in their evolution with good correlation between the
sonographic and pathological extent of necrosis immediately
after treatment. Subsequent regression by healing of these
areas was easily monitored by US. Histological follow up at
6-7 months showed all treatment areas had healed complete-
ly and safely leaving a small central scar.
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The effective and safe clinical application of ILH for liver
cancer depends on delineating the limits of the pathological
tissue under consideration and then accurately matching the
extent of thermal damage to it. Equally important is demon-
strable complete and safe healing. We embarked on a pilot
clinical study which had two principle objectives. The first to
assess the feasibility of ILH as a technique for inducing
necrosis in liver cancer and the second to determine if this
could be achieved safely. Our treatment selection criteria
were relatively flexible and included the following re-
quirements. A positive histological diagnosis of liver cancer
with no evidence of primary tumour or extrahepatic spread.
No more than four hepatic metastases, none exceeding a
diameter of 6 cm and all accessible to percutaneous puncture.
All patients to be unsuitable for hepatic resection or to have
refused surgery.
Method
Ten patients (median age 67 years, range 48-78 years) with a
total of 18 hepatic metastases (median diameter 3 cm, range 2.0-6.5cm) received a total of 31 laser treatments using a
percutaneous technique for fibre insertion. The primary
tumour site was the colon/rectum in seven patients with the
breast, stomach and a small bowl carcinoid each accounting
for the remaining three. Informed consent was obtained from
all patients. All treatments were performed using a con-
tinuous wave Nd:YAG laser (Flexilase, Living Technology,
Glasgow) coupled to a 1 x 4 200 micron (Ju) star coupler (Canstar, North York, Ontario, Canada). This allowed the
simultaneous transmission of laser light of equal intensity
down four fibres from a single output source emanating from
one laser. The first two patients in this series have been
briefly reported elsewhere (Steger et al., 1989).
Pre-treatment ultrasonography and a dynamic contrast
enhanced computerised tomographic (CT) scan were per- formed in all patients as a baseline to assess the enhancement
pattern, number, site and size of the metastases. Routine
biochemical and haematological profiles including a clotting
screen were also carried out. The procedure was performed under a combination of intravenous sedation and analgesia (Diazepam 5-10 mg and Pethidine 50-75 mg) together with
a 24 h regimen of intravenous prophylactic antibiotics (Fluc- loxacillin and Gentamicin). The abdominal wall was infil-
trated with 1% lignocaine at the intended puncture site.
Three to four hollow 19 gauge needles (diameter 0.8mm)
were inserted percutaneously into the selected metastasis
under US control (Figure 1) using a 3.5 MHz transducer
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Figure 1 3.5 MHz ultrasound transducer checking needle posi-
tions. Note the laser fibres (L) which have been inserted down
each needle so that the fibre tip lies within the metastasis.
(Aloka, Japan). The needles were in juxtaposition with a
separation of approximately 1.5 cm between individual
needles to ensure treatment of all intervening tissue. A freshly
cleaved, sterile 200 fibre from a 1 x 4 200 .t star coupler
was inserted down each needle such that 3-4 mm of bare
fibre tip lay within the metastasis. The laser was preset so
that a power of 1.5 to 2.0 watts per fibre applied for at least
500 s. The evolving thermal changes occurring at the treat-
ment site were monitored in real time by US. By adjusting
the position of the needles it was possible to photocoagulate
several sites within a metastasis at any given treatment
depending on its size and ensure that a 1 cm circumferential
rim of 'normal' liver around the metastasis was incorporated
into the treatment field.
The following day, repeat haematological and biochemical
screens were performed in conjunction with a full clinical
assessment. All patients were discharged within 24 h of treat-
ment. Follow up contrast enhanced CT scan was carried out
at 6 to 8 weeks from treatment combined with needle biop-
sies and serial tumour marker assays where appropriate.
Recently, we have changed our practice to include a 24 h
post-treatment CT scan as well. The extent of laser induced
necrosis was assessed by comparing the enhancement pattern
for a given metastasis on pre and post-treatment CT scans.
Areas of non enhancement which previously enhanced were
considered avascular and therefore necrotic as a result of
treatment. The volume of all metastases and regions of non
enhancement were assumed to be roughly spherical and cal-
culated from the formula 4/3 &r3. The radius r was calculated
as the mean of the radii in the x, y and z axis. The volume of
necrosis was then expressed as a percentage of the metastasis
volume at follow up. Any metastasis showing necrosis in
25% or greater of its volume was deemed to have had a
positive response to laser treatment.
Results
Pre-treatment US showed all metastases to be predominantly
mixed echogenic (Figure 2a). As photocoagulation com-
menced and progressed, real time US monitoring showed
gradual evolution of a spherical bright hyperechogenic zone
around each of the laser fibres (Figure 2b) which progres-
sively enlarged and coalesced. Immediately at the end of
treatment, a single well defined spherical hyperechogenic area
enveloped the treatment site (Figure 2c). This is thought to
represent the extent of induced thermal damage. For small
metastases (diameter < 3 cm) this hyperechogenic pattern
completely replaced the original mixed echogenic appearance,
while for larger metastases, this transformation allowed
delineation between treated and untreated areas (Figure 2c).
Pre-treatment dynamic contrast enhanced CT scans showed
all metastases to have low enhancement compared to normal
hepatic parenchyma. Where performed, the extent of non
enhancement of treated tumours was maximal on the 24 h
follow up scan (Figure 3a and b). By 2 months, CT imaging
revealed partial resolution of the non enhanced area with the
suggestion of normal liver ingrowth into the treated area. In
two out of three patients where needle biopsy showed
adenocarcinoma, follow up histology 4 to 6 weeks from
treatment showed normal liver architecture with extensive
fibrosis.
At a median follow up of 2 months, ten out of the 18
metastases trated (group A) showed radiological evidence of
at least partial necrosis. Of these ten metastases, seven
(diameter < 3.0cm) showed the largest percentage necrosis
by volume (30-100%) (Figure 4). On longer follow up
(median time of 6 months), five of the ten metastases in
group A with necrosis volumes greater than or equal to 70%
have remained the same size with the appropriate tumour
markers either remaining within normal limits or falling
significantly if previously elevated (Figure 5). Despite
evidence of partial necrosis, the remaining five metastases in
group A continued to increase in volume with rising tumour
marker titres. Over a similar follow up period, five patients
with eight metastases (Group B) not showing any response to
treatment fared badly with continued tumour growth and
three patients dying from disseminated extrahepatic malig-
nant disease. The median metastasis diameter for group A
was 2.0 cm and compares with a figure of 4.5 cm for group
B. The overall objective response rate in this pilot study was
44% (eight out of 18 metastases).
Untoward effects of treatment were minor. One patient
developed a self limiting vaso-vagal response during treat-
ment attributable to stimulation of the vagal plexus on a
nearby large blood vessel. A second patient complained of
shoulder tip pain probably due to stimulation of the diaph-
ragmatic peritoneum when treating a lesion high up under
the dome of the diaphragm. Most patients described mild
abdominal wall discomfort at the needle puncture sites but
this resolved spontaneously within 48-72 h of treatment in
most instances and rarely required more than mild oral
analgesia for relief. None of the patients developed any
evidence of primary or secondary haemorrhage, haemobilia,
bile leakage or sepsis within the liver despite a two to three
fold rise in the Aspartate Transaminase (AST) noted within
24 h of treatment in 14 of the 31 sessions carried out.
Discussion
Despite a certain amount of controversy, the benefits of
hepatic resection in suitable patients with colorectal hepatic
metastases are generally accepted. In series of major hepatic
resection for colorectal metastases recently published, the
operative mortality ranged from 4-12% (August et al., 1985;
Butler et al., 1986; Adson et al., 1984; Fortner, 1982) with up
to 25% of patients suffering a major complication (August et
al., 1985; Logan et al., 1982). Despite this, 20-40% of
patients who had undergone a resection could expect to
survive at least 5 years (Butler et al., 1986; Adson et al.,
1984; Cady & McDermott, 1985). For the vast majority of
patients with hepatic metastases, resection is an inappropriate
treatment. Chemotherapy administered systemically or re-
gionally to the liver can produce response rates of 17% and
62% respectively (Chang et al., 1987). However, the higher
response rate is accompanied by an unacceptable incidence of
serious complications with no significant improvement in
survival times (Chang et al., 1987; Grage et al., 1979). Alter-
native palliative therapy such as hepatic irradiation, hepatic520 A. MASTERS et al.
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Figure 2 a Ultrasound apearance of a 4.0 cm diameter mixed echogenic colorectal metastasis (arrowed) prior to laser treatment. b
The appearance of the same lesion (arrowed) halfway through a 500 s exposure at a power of 2.0 watts per fibre. There are three
hyperechogenic foci (numbered) each developing around one of the three fibres used. c The same metastasis (arrowed) immediately
at the end of treatment. There is a well defined confluent hyperechogenic area occupying the right half of the lesion. There is clear
distinction between the treated (T) and untreated (U) portions.ILH FOR HEPATIC METASTASES 521
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Figure 4 This graph illustrates the relationship between meta-
stasis diameter and extent of laser mediated necrosis. The smaller
metastases developed the largest volumes of necrosis. Zero
represents those eight metastases showing no response to treat-
b ment.
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Figure 3 a, Contrast enhanced CT scan showing a poorly
enhancing 2.0cm diameter colonic metastasis deep in the right
lobe (arrowed). Note the central calcification, a characteristic of
colorectal hepatic metastases. b The same metastasis (arrowed)
24 h following laser treatment. It now appears as a filling defect
as it has been rendered avascular following laser treatment and is
unable to concentrate any contrast medium.
dearterialisation, embolisation and hepatic artery ligation can
produce a limited reponse in selected patient groups at a cost
of significant morbidity and no convincing survival benefits
(Taylor, 1985; Bengmark, 1989).
The first clinical work using ILH for liver tumours was
reported by Hashimoto and his colleagues in Japan
(Hashimoto, 1985). Ten patients (two with hepatocellular
carcinoma and eight with colorectal hepatic metastases) were
treated at laparotomy using US guidance and a Nd:YAG
laser. The patients, who all had elevated serum markers of
malignancy, showed dramatic falls in their titres within 3
months of treatment suggesting significant reduction in
tumour bulk. There were no treatment related problems, but
what influence this treatment had on patient survival is not
known. Adopting a similar technique to that used by
Hashimoto, Schroeder et al. treated four patients with
advanced malignant disease of the liver (Schroeder, 1989).
All patients showed radiological and cytological evidence of
tumour necrosis within 2 weeks of treatment. However, one
patient developed an infection in a laser induced necrotic
area and another died from an air embolus originating from
coaxial gas used to cool the sapphire tip on the fibre.
Figure 5 Flow chart demonstrating the longer term effect of
laser therapy on those metastases which showed a response. Five
out of ten metastases have remained the same diameter with
normal or falling tumour marker titres. FU = Follow up, CEA =
Carcino-embryonic antigen, 5 HIAA = 5 Hydroxyindole acetic
acid, ISQ = In status quo, WNL = Within normal limits.
Palliative therapy for malignant disease should be simple
to perform, require the minimum of hospitalisation time and
cause little or no side effects to the patient. In this regard,
Hashimoto and Schroeder's operative approach for fibre
positioning is undesirable. Our pilot study has shown that
laser fibres can be positioned percutaneously with relative
accuracy and that ILH is a feasible and inherently safe
technique for inducing necrosis in hepatic metastases. As a
consequence, hospitalisation times are kept to a minimum
and the low risk of any serious side effects makes our techni-
que highly acceptable to patients. Our policy to treat a
peripheral rim of 'normal' liver around a metastasis ensured
any adjacent microscopic or satellite deposits were incor-
porated in the treatment field. The overall response rate in
our small series was 44% (ten metastases out of 18) with
36% (five metastases out of 18) showing no growth over the
follow up period. Clearly, smaller metastases (diameter
< 3 cm) were most successfully treated. This reflects the
relative ease which the volume of necrosis produced using a
four fibre system can 'cover' the volume occupied by a small
metastasis. The overlap factor may be as high as 100%. For
larger metastases, several manipulations of the laser fibres
were required during a treatment to achieve sufficient 'cover'
of tumour volume. This may introduce errors in needle place-
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ment so that intervening areas of viable tumour between
successive treatment sites may go unrecognised and escape
treatment. From a practical point of view, it can be difficult
to achieve accurate needle placement and separation when
attempting to treat small deep seated tumours high in the
right lobe and may account for the absence of necrosis in
two small metastases in our series. The window of oppor-
tunity for imaging the volume of necrosis at its maximum is
likely to occur within a short time from treatment. In this
respect, by imaging patients relatively late, we are probably
underestimating the extent of necrosis due to continuous
resorption and healing of the treated area. We have now
modified out follow up protocol to take this factor into
account.
Metastases in close proximity of major blood vessels are
unresectable but may be treated in relative safety using ILH
as rapid blood flow within such vessels exert a heat sink
effect. This in turn confers a degree of protection to the
vessel wall. However, major biliary radicles are sensitive to
thermal insults and inflammatory strictures are likely to
develop. Another limiting factor is the resolution capability
of US in detecting small metastases. A soft tissue interface
between the scanning probe and the liver prevents reliable
detection and subsequent treatment of metastases less than
2 cm in diameter.
Alternative interstitial techniques such as cryotherapy,
alcohol injection and interstitial radiotherapy have their
advocates and are currently the focus of active research. Pilot
clinical trials have shown these methods to be feasible and
safe, however, they are not without their drawbacks
(Masters, 1991).
ILH is a technique in its infancy. Further research is
necessary to improve its efficacy for both small and large
metastases. Improved dosimetery or increasing the number of
fibres inserted into a tumour would allow a more generous
margin of 'overkill' when matching the extent of necrosis to
tumour volume minimising fibre manipulation in treating
large metastases. Improvement in accuracy of needle place-
ment and separation for deeply seated tumours is likely to be
achieved using CT guidance. Invasive probes which monitor
changes in blood flow, temperature and light transmission
may have a complementary role in conjunction with US or
magnetic resonance imaging in providing a more detailed
dynamic assessment of the effects of treatment as it is being
performed. This would allow appropriate adjustments to be
made in laser parameters or fibre position.
For the moment, it has to be acknowledged that the
influence of ILH on patient survival is unknown. However, it
is easy to perform, is well tolerated and for small metastases,
produces radiological evidence of tumour necrosis. Its future
role in controlling the growth of relatively small well defined
tumour volumes within the liver and possible effect on
patient survival is worthy of further research. Patients with a
small number of discrete metastases unsuitable for surgery
and with no prospect for conventional palliative treatment
should now be offered this treatment. With further
refinements, it is conceivable that ILH may become a
curative modality and challenge the role of surgery in the
management of primary and secondary hepatic tumours.
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